Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Retained Earnings (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Retained Earnings for 12 consecutive years, with -$1.5 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 18.63% year-over-year to -$1.5 billion; the TTM value through Mar 2026 reached -$1.5 billion, down 18.63%, while the annual FY2025 figure was -$1.5 billion, 23.37% down from the prior year.
  • Retained Earnings hit -$1.5 billion in Q1 2026 for Syndax Pharmaceuticals, down from -$1.5 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$580.9 million in Q1 2022 and bottomed at -$1.5 billion in Q1 2026.
  • Average Retained Earnings over 5 years is -$1.0 billion, with a median of -$974.8 million recorded in 2024.
  • Year-over-year, Retained Earnings increased 2.6% in 2022 and then tumbled 35.79% in 2024.
  • Syndax Pharmaceuticals' Retained Earnings stood at -$693.0 million in 2022, then tumbled by 30.21% to -$902.4 million in 2023, then plummeted by 35.32% to -$1.2 billion in 2024, then dropped by 23.37% to -$1.5 billion in 2025, then decreased by 2.83% to -$1.5 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$1.5 billion, -$1.5 billion, and -$1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.